OnQuality Pharmaceuticals develops targeted supportive care treatments that mitigate the side effects of specific cancer therapies, enabling patients to maintain their treatment regimens. By addressing dose-limiting toxicities, the company enhances the quality of life for cancer patients undergoing anti-cancer therapy.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies induce dose-limiting toxicities and side effects that can force patients to reduce dosage or halt treatment, negatively impacting their quality of life and treatment outcomes. Current pharmaceutical development is disproportionately focused on oncology therapeutic drugs, leaving treatment gaps in supportive care.
Solution
OnQuality Pharmaceuticals develops targeted supportive care treatments designed to mitigate the specific side effects caused by cancer therapies. By preventing and treating these intolerable side effects, OnQuality's products enable patients to maintain their treatment regimens and improve their quality of life. The company focuses on addressing dose-limiting toxicities where treatment gaps exist, aiming to make fighting cancer easier for patients undergoing anti-cancer therapy.
Target Audience
The primary target audience includes cancer patients undergoing anti-cancer therapy and the oncology healthcare providers who manage their treatment and supportive care.
Features
- Developing OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash
- Developing OQL051, indication not specified
- Developing OQL036, indication not specified
- Conducting NOVA-II Phase 2 Clinical Trial (expanded to China and India)